We can’t show the full text here under this license. Use the link below to read it at the source.
Reduction of MLH1 and PMS2 confers temozolomide resistance and is associated with recurrence of glioblastoma
Lower levels of MLH1 and PMS2 are linked to temozolomide resistance and glioblastoma returning
AI simplified
Abstract
A reduction in expression of MLH1 and PMS2 was observed in TMZ-resistant glioblastoma cells.
- DNA repair deficiency is related to temozolomide (TMZ) resistance in glioblastoma.
- Three TMZ-resistant human glioblastoma cell lines were isolated for analysis.
- Reduced levels of MLH1 were associated with decreased PMS2 protein levels in resistant cells.
- Knockdown of MLH1 or PMS2 resulted in increased resistance to TMZ.
- Recurrent glioblastoma tumors exhibited lower expression of MLH1 and PMS2 compared to primary tumors.
AI simplified